Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
2
33%
Ph phase_2
2
33%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
unknown1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

completed350%
unknown117%
not_yet_recruiting117%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_2

24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients

NCT03702829
not_yet_recruiting

TEGSEDI Pregnancy Surveillance Program

NCT04270058
completedphase_3

NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

NCT04136184
completedphase_3

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

NCT02175004
unknown

ATTR Expanded Access Program (EAP) by Ionis

NCT03400098
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03702829Phase 2

24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients

Terminated
NCT04270058

TEGSEDI Pregnancy Surveillance Program

Not Yet Recruiting
NCT04136184Phase 3

NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Completed
NCT02175004Phase 3

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Completed
NCT03400098

ATTR Expanded Access Program (EAP) by Ionis

Unknown
NCT01737398Phase 2

Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6